MA51327A - Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar - Google Patents

Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar

Info

Publication number
MA51327A
MA51327A MA051327A MA51327A MA51327A MA 51327 A MA51327 A MA 51327A MA 051327 A MA051327 A MA 051327A MA 51327 A MA51327 A MA 51327A MA 51327 A MA51327 A MA 51327A
Authority
MA
Morocco
Prior art keywords
diaryl
substituted
compounds used
cyclic compounds
c5ar inhibitors
Prior art date
Application number
MA051327A
Other languages
English (en)
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Rajinder Singh
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA51327A publication Critical patent/MA51327A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA051327A 2017-12-22 2018-12-20 Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar MA51327A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762609844P 2017-12-22 2017-12-22

Publications (1)

Publication Number Publication Date
MA51327A true MA51327A (fr) 2021-05-26

Family

ID=66950014

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051327A MA51327A (fr) 2017-12-22 2018-12-20 Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar

Country Status (15)

Country Link
US (2) US10759807B2 (fr)
EP (1) EP3728202A4 (fr)
JP (1) JP7253557B2 (fr)
KR (1) KR20200110656A (fr)
CN (1) CN111788184B (fr)
AU (1) AU2018388657C1 (fr)
BR (1) BR112020012374A2 (fr)
CA (1) CA3086111A1 (fr)
IL (1) IL275516B2 (fr)
MA (1) MA51327A (fr)
MX (1) MX2020006460A (fr)
NZ (1) NZ765590A (fr)
SG (1) SG11202005799XA (fr)
TW (1) TWI817968B (fr)
WO (1) WO2019126431A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48803A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
EP3630774B1 (fr) 2017-05-31 2022-11-23 ChemoCentryx, Inc. Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
KR20200109316A (ko) 2017-12-22 2020-09-22 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
CA3086111A1 (fr) 2017-12-22 2019-06-27 Chemocentryx, Inc. Composes cycliques fusionnes en 5,5 a substitution diaryle, utilises en tant qu'inhibiteurs du c5ar
US20190300526A1 (en) * 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
EP4005638A4 (fr) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP3886858B1 (fr) 2019-12-19 2022-05-11 Active Biotech AB Composés pour le traitement de maladies des yeux associées à une vascularisation excessive
WO2021222971A1 (fr) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Traitement du syndrome de détresse respiratoire aiguë induite par un virus
WO2021222972A1 (fr) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Traitement du syndrome de détresse respiratoire aiguë
IL297965A (en) * 2020-05-07 2023-01-01 Ac Immune Sa New compounds for diagnosis
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
EP4237411A1 (fr) 2020-10-28 2023-09-06 ChemoCentryx, Inc. Méthodes de traitement de l'hidradénite suppurée
KR20230149402A (ko) * 2022-04-20 2023-10-27 목포대학교산학협력단 판막 석회화 예방 또는 치료용 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001169A (es) * 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
WO2002088122A1 (fr) 2001-04-26 2002-11-07 Ajinomoto Co., Inc. Composes heterocycliques
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487796A4 (fr) 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
EP1487798A4 (fr) 2002-03-28 2005-07-13 Neurogen Corp Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
CA2504941C (fr) 2002-11-08 2012-06-26 Neurogen Corporation 6-arylpyridines substituees en position 3
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
CN101318961B (zh) * 2003-09-17 2012-11-28 詹森药业有限公司 稠合杂环化合物
WO2006042102A2 (fr) 2004-10-05 2006-04-20 Neurogen Corporation Composes de pyrrolo-pyridine, de pyrrolo-pyrimidine et composes heterocycliques apparentes
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (fr) 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010075257A1 (fr) 2008-12-22 2010-07-01 Chemocentryx, Inc. Antagonistes de c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
SG11201501133WA (en) * 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
MA48803A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
EP3630774B1 (fr) 2017-05-31 2022-11-23 ChemoCentryx, Inc. Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
CA3086111A1 (fr) 2017-12-22 2019-06-27 Chemocentryx, Inc. Composes cycliques fusionnes en 5,5 a substitution diaryle, utilises en tant qu'inhibiteurs du c5ar
KR20200109316A (ko) 2017-12-22 2020-09-22 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
US20190300526A1 (en) 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Also Published As

Publication number Publication date
AU2018388657A1 (en) 2020-07-09
US20210009596A1 (en) 2021-01-14
JP7253557B2 (ja) 2023-04-06
US20190194208A1 (en) 2019-06-27
AU2018388657C1 (en) 2023-03-23
TWI817968B (zh) 2023-10-11
IL275516B1 (en) 2023-08-01
RU2020124094A (ru) 2022-01-24
CA3086111A1 (fr) 2019-06-27
KR20200110656A (ko) 2020-09-24
WO2019126431A1 (fr) 2019-06-27
NZ765590A (en) 2024-01-26
AU2018388657B2 (en) 2022-12-01
CN111788184A (zh) 2020-10-16
EP3728202A4 (fr) 2021-05-26
US11485737B2 (en) 2022-11-01
EP3728202A1 (fr) 2020-10-28
SG11202005799XA (en) 2020-07-29
CN111788184B (zh) 2023-12-22
TW201934552A (zh) 2019-09-01
JP2021506900A (ja) 2021-02-22
BR112020012374A2 (pt) 2020-11-24
IL275516B2 (en) 2023-12-01
US10759807B2 (en) 2020-09-01
MX2020006460A (es) 2020-11-06
IL275516A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MA51327A (fr) Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MA51331A (fr) COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR
MA54169A (fr) Tolyles substitués utilisés en tant que fongicides
MA56398A (fr) Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA51530A (fr) Composés cycliques fondus
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA53008A (fr) Composés azole-amide à action pesticide
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EA201691701A1 (ru) Применение 3-изоксазолидиноновых соединений в качестве селективных гербицидов
MA52948A (fr) Composés
MA47420A (fr) Composés inhibiteurs d'oga
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA53003A (fr) Composés